ライフサイエンスコーパス: broadly neutralizing antibody

1 some that could escape from an RBS-targeted broadly neutralizing antibody.

2 an amazing class of immunoglobulins known as broadly neutralizing antibodies.

3 lope glycoprotein spike that are targets for broadly neutralizing antibodies.

4 stics, or neutralization profiles of nascent broadly neutralizing antibodies.

5 ecific antibodies, including known and novel broadly neutralizing antibodies.

6 future efforts to design vaccines to induce broadly neutralizing antibodies.

7 of a conserved epitope that is the target of broadly neutralizing antibodies.

8 ventative or therapeutic strategies based on broadly neutralizing antibodies.

9 ts and macaques, but so far failed to induce broadly neutralizing antibodies.

10 al immunity, such as therapeutic vaccines or broadly neutralizing antibodies.

11 e relatively resistant to State 1-preferring broadly neutralizing antibodies.

12 e, surface-presented Env, and are targets of broadly neutralizing antibodies.

13 nsive effort to identify a vaccine to elicit broadly neutralizing antibodies.

14 ute to or influence the epitopes of numerous broadly neutralizing antibodies.

15 tionally inferred germline sequences, to HIV broadly neutralizing antibodies.

16 that may lead to the eventual elicitation of broadly neutralizing antibodies.

17 ts of recognition by some of the most potent broadly neutralizing antibodies.

18 dition to the MPER on gp41 for generation of broadly neutralizing antibodies.

19 al for virus entry, is recognized by several broadly neutralizing antibodies.

20 cines against HIV most likely need to elicit broadly neutralizing antibodies.

21 cting virus, which in some cases mature into broadly neutralizing antibodies.

22 V-1 gp41 contains epitopes for at least four broadly neutralizing antibodies.

23 nd serves as a target for some highly potent broadly neutralizing antibodies.

24 e molecular mechanism of MPER recognition by broadly neutralizing antibodies.

25 rmation that presents epitopes recognized by broadly neutralizing antibodies.

26 tibodies, which resemble precursors of human broadly neutralizing antibodies.

27 elding HIV-1 from recognition by V3-directed broadly neutralizing antibodies.

28 as delayed significantly by treatment with a broadly neutralizing antibody, 10-1074, compared to trea

29 hat treatment of these humanized mice with a broadly neutralizing antibody, 10-1074, depleted the pat

30 e anti-HIV-1 envelope glycoprotein 41 (gp41) broadly neutralizing antibody 4E10 suggest that 4E10 als

31 Development of high avidity, broadly neutralizing antibodies (Abs) is a priority afte

32 Broadly neutralizing antibodies (Abs) that bind the infl

33 ghly immunogenic in cotton rats and elicited broadly neutralizing antibodies against a diverse panel

34 s potential vaccinology strategies to elicit broadly neutralizing antibodies against coronaviruses.

35 The vaccine elicitation of broadly neutralizing antibodies against HIV-1 is a long-

36 properties.IMPORTANCE One approach to elicit broadly neutralizing antibodies against HIV-1 is to stab

37 been proposed to restrict the development of broadly neutralizing antibodies against HIV-1, but this

38 re contacts for recognition by V1V2-targeted broadly neutralizing antibodies against HIV-1.

39 membranes, similar to the action of certain broadly neutralizing antibodies against influenza hemagg

40 Induction of broadly neutralizing antibodies against most HCV genotyp

41 ementarity-determining region loops of human broadly neutralizing antibodies against the hemagglutini

42 ing efforts to generate vaccines that induce broadly neutralizing antibodies against viral pathogens,

43 to how antibodies develop, in particular for broadly-neutralizing antibodies against HIV and influenz

44 iruses with neutralization titers against 16 broadly neutralizing antibodies and 30 sera from chronic

45 Most broadly neutralizing antibodies and many entry inhibitor

46 nd colleagues describe the co-evolution of a broadly neutralizing antibody and the virus that trigger

47 , enhanced or maintained the binding of most broadly neutralizing antibodies, and decreased the bindi

48 izing antibodies, especially the epitopes of broadly neutralizing antibodies, and these mutations ten

49 nd that is preferentially stabilized by many broadly neutralizing antibodies-and thus of interest for

50 Broadly neutralizing antibodies are also promising candi

51 IV-1 vaccine is of paramount importance, and broadly neutralizing antibodies are likely to be a key c

52 These so-called broadly neutralizing antibodies are readily detected in

53 mune responses, however, and the epitopes of broadly neutralizing antibodies are unknown.

54 istant microbes are undesired yet prevalent, broadly-neutralizing antibodies are much wanted but rare

55 f the human immunodeficiency virus 1 (HIV-1) broadly neutralizing antibody b12 (iglb12).

56 Furthermore, monotherapy with the potent broadly neutralizing antibody Bc1.187 suppressed viremia

57 Broadly neutralizing antibodies (bNAb) may further reduc

58 that a single subcutaneous administration of broadly neutralizing antibody (bNAb) 10-1074 conferred d

59 nd CD4-Ig and >100-fold more potent than the broadly neutralizing antibody (bNAb) 3BNC117, with >12,0

60 CRF01_AE T/F100) complexed with Fab from the broadly neutralizing antibody (bNAb) 8ANC195.

61 that are recognized by trimer cross-reactive broadly neutralizing antibody (bnAb) and not by nonneutr

62 Remarkably, we identified multiple broadly neutralizing antibody (bNAb) combinations that w

63 evolution and structural changes involved in broadly neutralizing antibody (bnAb) development holds g

64 A combination of passive broadly neutralizing antibody (bnAb) infusion and active

65 Elicitation of broadly neutralizing antibody (bNAb) responses is a majo

66 While many barriers to vaccine induction of broadly neutralizing antibody (bNAb) responses remain, e

67 During hepatitis C virus (HCV) infection, broadly neutralizing antibody (bNAb) responses targeting

68 t is an ability to elicit strong and durable broadly neutralizing antibody (bNAb) responses.

69 VRC01 is an HIV-1 CD4 binding site broadly neutralizing antibody (bnAb) that is active agai

70 loop bnAbs.IMPORTANCE The efficacy of HIV-1 broadly neutralizing antibody (bnAb) therapies may be co

71 We showed previously that short-term broadly neutralizing antibody (bNAb) therapy given 24 h

72 the efficacy of two vaccine candidates and a broadly neutralizing antibody (bNAb) to prevent HIV-1 in

73 ely be insufficient for the development of a broadly neutralizing antibody (bnAb) vaccine for HIV or

74 will uncover whether passive infusion of the broadly neutralizing antibody (bNAb) VRC01 can protect a

75 The broadly neutralizing antibody (bnAb) VRC01 is being eval

76 region in B cell lines with that from an HIV broadly neutralizing antibody (bnAb), PG9.

77 e of BF520.1, an infant-derived HIV-specific broadly neutralizing antibody (bnAb), using computationa

78 A major obstacle to a broadly neutralizing antibody (bnAb)-based HIV vaccine i

79 The growing availability of HIV-1 broadly neutralizing antibodies (BNAbs) affords the oppo

80 ction of HIV-1 patients are able to generate broadly neutralizing antibodies (bNAbs) after 2 to 4 yea

81 The latter show biased usage in human broadly neutralizing antibodies (bnAbs) against both HIV

82 idenced by the induction of higher titers of broadly neutralizing antibodies (bNAbs) against cell cul

83 HIV-1 vaccine development aims to elicit broadly neutralizing antibodies (bnAbs) against diverse

84 e and proposes that engineered expression of broadly neutralizing antibodies (bNAbs) against HIV-1 co

85 Broadly neutralizing antibodies (bNAbs) against HIV-1 en

86 e nnAbs are demonstrably less effective than broadly neutralizing antibodies (bNAbs) against HIV-1 in

87 Broadly neutralizing antibodies (bnAbs) against HIV-1 pr

88 Broadly neutralizing antibodies (bnAbs) against HIV-1 pr

89 Efforts to elicit broadly neutralizing antibodies (bNAbs) against HIV-1 re

90 l fraction of HIV-1- infected humans develop broadly neutralizing antibodies (bNAbs) against HIV-1 th

91 Development of broadly neutralizing antibodies (bnAbs) against HIV-1 us

92 sign is an attractive approach for eliciting broadly neutralizing antibodies (bNAbs) against HIV-1.

93 st blocking of viral infection by a class of broadly neutralizing antibodies (bnAbs) against human im

94 Broadly neutralizing antibodies (bNAbs) against human im

95 The discovery of potent and broadly neutralizing antibodies (bNAbs) against human im

96 Recent characterization of broadly neutralizing antibodies (bnAbs) against influenz

97 cent discovery and characterization of human broadly neutralizing antibodies (bnAbs) against influenz

98 Eliciting broadly neutralizing antibodies (bNAbs) against the four

99 The identification of multiple broadly neutralizing antibodies (bNAbs) against the HIV-

100 Broadly neutralizing antibodies (bNAbs) against the HIV-

101 The elicitation of broadly neutralizing antibodies (bNAbs) against the HIV-

102 A number of highly potent and broadly neutralizing antibodies (bNAbs) against the huma

103 Broadly neutralizing antibodies (bnAbs) against the N332

104 Induction of broadly neutralizing antibodies (bnAbs) against this div

105 from 1 to 2 years postinfection (p.i.) with broadly neutralizing antibodies (bnAbs) against tier 2 H

106 Broadly neutralizing antibodies (bNAbs) against V1V2 loo

107 thout loss of viral fitness.IMPORTANCE HIV-1 broadly neutralizing antibodies (bNAbs) and engineered a

108 In this study, a panel of broadly neutralizing antibodies (bnAbs) and nnAbs, inclu

109 sted to quantify neutralization titers by 16 broadly neutralizing antibodies (bnAbs) and sera from 30

110 pe glycoprotein (Env) is the sole target for broadly neutralizing antibodies (bnAbs) and the focus fo

111 SOSIP trimers) present multiple epitopes for broadly neutralizing antibodies (bNAbs) and their germli

112 , ch.SOSIP trimers retained their binding to broadly neutralizing antibodies (bNAbs) and to their unm

113 V3-glycan-targeting broadly neutralizing antibodies (bNAbs) are a focus of H

114 eneration (universal) influenza vaccines and broadly neutralizing antibodies (bNAbs) are in clinical

115 A subset of characterized HIV-1 broadly neutralizing antibodies (bnAbs) are polyreactive

116 Potent and broadly neutralizing antibodies (bnAbs) are the hallmark

117 Broadly neutralizing antibodies (bNAbs) are typically is

118 Broadly neutralizing antibodies (bNAbs) block infection

119 se trimers display the epitopes for multiple broadly neutralizing antibodies (bNAbs) but can also exp

120 s Env in a closed conformation antigenic for broadly neutralizing antibodies (bnAbs) but not for thir

121 Induction of broadly neutralizing antibodies (bNAbs) by HIV-1 envelop

122 attractive vaccine target for elicitation of broadly neutralizing antibodies (bNAbs) by vaccination.

123 To understand how broadly neutralizing antibodies (bNAbs) can be elicited,

124 HIV-1-specific broadly neutralizing antibodies (bNAbs) can protect rhes

125 HIV broadly neutralizing antibodies (bnAbs) can suppress vir

126 Induction of broadly neutralizing antibodies (bnAbs) capable of inhib

127 The induction by vaccination of broadly neutralizing antibodies (bNAbs) capable of neutr

128 Such broadly neutralizing antibodies (bnAbs) could in the fut

129 HIV-1 broadly neutralizing antibodies (bnAbs) develop in a sub

130 Broadly neutralizing antibodies (bnAbs) develop in a sub

131 ediates virus entry and is a major target of broadly neutralizing antibodies (bnAbs) developed during

132 ferred germline (iGL) forms of several HIV-1 broadly neutralizing antibodies (bNAbs) did not display

133 wever, mounting evidence suggests that these broadly neutralizing antibodies (bNAbs) do emerge natura

134 In clinical trials, HIV-1 broadly neutralizing antibodies (bnAbs) effectively lowe

135 Broadly neutralizing antibodies (bnAbs) elicited in HIV-

136 Most broadly neutralizing antibodies (BNAbs) elicited in resp

137 Understanding the mechanism(s) by which broadly neutralizing antibodies (bNAbs) emerge naturally

138 Here, we review how broadly neutralizing antibodies (bnAbs) exploit these ev

139 munized macaque suggests that elicitation of broadly neutralizing antibodies (bNAbs) for ebolaviruses

140 A new class of broadly neutralizing antibodies (bNAbs) from HIV donors

141 for antibody affinity maturation, with HIV-1 broadly neutralizing antibodies (bnAbs) generally requir

142 The development of HIV broadly neutralizing antibodies (bNAbs) has previously b

143 Broadly neutralizing antibodies (bNAbs) have been develo

144 Broadly neutralizing antibodies (bNAbs) have been evalua

145 Broadly neutralizing antibodies (bNAbs) have been isolat

146 HIV broadly neutralizing antibodies (bnAbs) have been shown

147 However, while a number of HIV-1 broadly neutralizing antibodies (bnAbs) have demonstrate

148 es of BG505 SOSIP.664 trimer in complex with broadly neutralizing antibodies (bNAbs) have revealed th

149 Anti-HIV broadly neutralizing antibodies (bnAbs) have revealed va

150 ent is to define envelope (Env) evolution of broadly neutralizing antibodies (bnAbs) in infection and

151 enefit from understanding the development of broadly neutralizing antibodies (bnAbs) in rhesus macaqu

152 re and dynamics of E2 and favor induction of broadly neutralizing antibodies (bNAbs) in the context o

153 approaches for selective clonal induction of broadly neutralizing antibodies (bnAbs) inform most curr

154 coprotein (Env) immunogen for elicitation of broadly neutralizing antibodies (bNAbs) is a challenging

155 Eliciting protective titers of HIV-1 broadly neutralizing antibodies (bnAbs) is a goal of HIV

156 Induction of broadly neutralizing antibodies (bNAbs) is a major goal

157 The induction of broadly neutralizing antibodies (bNAbs) is a major goal

158 Induction of broadly neutralizing antibodies (bnAbs) is a major HIV v

159 Induction of broadly neutralizing antibodies (bnAbs) is a primary goa

160 Elicitation of broadly neutralizing antibodies (bnAbs) is a primary HIV

161 Developing HIV-1 vaccines that trigger broadly neutralizing antibodies (bnAbs) is a priority as

162 trol of the HIV pandemic, and elicitation of broadly neutralizing antibodies (bnAbs) is likely to be

163 es of E2 complexes with front layer-specific broadly neutralizing antibodies (bNAbs) isolated from HC

164 l agents are the mainstay for treatment, but broadly neutralizing antibodies (bNAbs) may be a viable

165 y, chronically HIV-infected children develop broadly neutralizing antibodies (bnAbs) more frequently

166 120 envelope glycoprotein of HIV-1 and three broadly neutralizing antibodies (bNAbs) of the VRC01 cla

167 Broadly neutralizing antibodies (bNAbs) offer new avenue

168 smitted/founder virus B41 SOSIP.664 Env with broadly neutralizing antibodies (bNAbs) PGT124 and 35O22

169 apex mode of recognition like that of human broadly neutralizing antibodies (bNAbs) PGT145 and PCT64

170 Increasing evidence indicates that broadly neutralizing antibodies (bNAbs) play an importan

171 Human anti-HIV-1 broadly neutralizing antibodies (bNAbs) protect against

172 Eliciting HIV-1-specific broadly neutralizing antibodies (bNAbs) remains a challe

173 of a preventative HIV vaccine able to elicit broadly neutralizing antibodies (bNAbs) remains a major

174 Potent broadly neutralizing antibodies (bNAbs) represent a pote

175 Broadly neutralizing antibodies (bNAbs) represent a prom

176 Broadly neutralizing antibodies (bNAbs) represent a prom

177 Broadly neutralizing antibodies (bNAbs) target five majo

178 Induction of broadly neutralizing antibodies (bnAbs) targeting conser

179 ptor-mimetic peptide improves the potency of broadly neutralizing antibodies (bNAbs) targeting five m

180 Majority of the broadly neutralizing antibodies (bnAbs) targeting HIV-1

181 ometry and confocal microscopy, we show that broadly neutralizing antibodies (bNAbs) targeting the "c

182 Broadly neutralizing antibodies (bNAbs) targeting the HI

183 Passively administered broadly neutralizing antibodies (bNAbs) targeting the HI

184 patitis C virus (HCV) is the major target of broadly neutralizing antibodies (bNAbs) that are critica

185 Detection of broadly neutralizing antibodies (bnAbs) that interact wi

186 Induction of multiple broadly neutralizing antibodies (bNAbs) that target dist

187 ful HIV-1 vaccine will likely need to elicit broadly neutralizing antibodies (bNAbs) that target the

188 lected individuals produced shared clones of broadly neutralizing antibodies (bNAbs) that targeted 3

189 Detailed studies of the broadly neutralizing antibodies (bNAbs) that underlie th

190 ss HIV-1 clades and the ability of anti-MPER broadly neutralizing antibodies (BNAbs) to block viral h

191 Induction of HIV-1 broadly neutralizing antibodies (bnAbs) to date has only

192 Broadly neutralizing antibodies (bnAbs) to HIV delineate

193 Understanding how broadly neutralizing antibodies (bnAbs) to HIV envelope

194 Broadly neutralizing antibodies (bNAbs) to HIV often hav

195 Vaccine induction of broadly neutralizing antibodies (bnAbs) to HIV remains a

196 Understanding how broadly neutralizing antibodies (bnAbs) to influenza hem

197 in (Delta123) increases the ability of human broadly neutralizing antibodies (bNAbs) to inhibit E2-CD

198 -dependent functions improve the capacity of broadly neutralizing antibodies (BnAbs) to protect again

199 erapy against HIV-1 will most likely require broadly neutralizing antibodies (bnAbs) with maximum bre

200 d a focus for development of novel vaccines, broadly neutralizing antibodies (bnAbs), and therapeutic

201 e patch on HIV Env is a preferred target for broadly neutralizing antibodies (bnAbs), but to date, no

202 -cycle viral infectivity and bind to several broadly neutralizing antibodies (bNAbs), including trime

203 Some HIV-1-infected human subjects develop broadly neutralizing antibodies (bnAbs), such as the pot

204 infected patients develop antibodies, called broadly neutralizing antibodies (bnAbs), that have a hig

205 Broadly neutralizing antibodies (bNAbs), whilst exhibiti

206 o many diverse strains of the virus-known as broadly neutralizing antibodies (bnAbs)-could protect ag

207 optimized to be recognized by Env V3/glycan broadly neutralizing antibodies (bnAbs).

208 vaccine candidates aimed at the induction of broadly neutralizing antibodies (bNAbs).

209 identification of a new generation of potent broadly neutralizing antibodies (bNAbs).

210 uccessful immunization approach for inducing broadly neutralizing antibodies (bnAbs).

211 vaccine candidates aimed at the induction of broadly neutralizing antibodies (bNAbs).

212 ponent of the HIV envelope protein (Env) for broadly neutralizing antibodies (bnAbs).

213 Many HIV-1-infected patients evolve broadly neutralizing antibodies (bnAbs).

214 c diversity and the difficulty of generating broadly neutralizing antibodies (bnAbs).

215 the target of vaccine development to elicit broadly neutralizing antibodies (bnAbs).

216 rstanding of the mechanisms of resistance to broadly neutralizing antibodies (bNAbs).

217 oprotein (Env) is the major target for HIV-1 broadly neutralizing antibodies (bNAbs).

218 ularly the elicitation of and recognition by broadly neutralizing antibodies (bnAbs).

219 e glycoprotein (Env) is targeted by multiple broadly neutralizing antibodies (bnAbs).

220 ystem but also acts as a target for anti-HIV broadly neutralizing antibodies (bnAbs).

221 s of naive human VRC01-class B cells and HIV broadly neutralizing antibodies (bnAbs).

222 1) that is preferentially recognized by many broadly neutralizing antibodies (bNAbs).

223 envelope protein (Env) is recognized by most broadly neutralizing antibodies (bnAbs).

224 of FWR mutations during maturation of HIV-1 broadly neutralizing antibodies (bnAbs).

225 ment is the design of immunogens that induce broadly neutralizing antibodies (bnAbs).

226 in vaccination strategies aimed at inducing broadly neutralizing antibodies (bNAbs).

227 mely cross-reactive neutralizing antibodies [broadly neutralizing antibodies (bNAbs)].

228 rse HIV-1 primary virus isolates (designated broadly neutralizing antibodies [bNAbs]) remains a high

229 orts toward an HIV vaccine focus on inducing broadly neutralizing antibodies, but eliciting both neut

230 ve one, which would help in the induction of broadly neutralizing antibodies by HIV-1 vaccines based

231 Although passive transfer of anti-HIV-1 broadly neutralizing antibodies can protect mice or maca

232 The findings suggest that a single broadly neutralizing antibody can prevent acute HCV infe

233 the potency and magnitude of multiple HIV-1 broadly neutralizing antibody classes are decreased duri

234 Here, inspired by the search for broadly neutralizing antibodies during B cell affinity m

235 ell control in primates, and host control of broadly neutralizing antibody elicitation have given ris

236 Ideally, Env immunogens should present broadly neutralizing antibody epitopes but limit the pre

237 ndividual glycans are components of multiple broadly neutralizing antibody epitopes, while shielding

238 ralizing antibodies to HVR1 and by shielding broadly neutralizing antibodies from their epitopes.

239 Here we describe an MPER broadly neutralizing antibody from the major IgG1 subcla

240 Influenza virus stem-reactive (SR) broadly neutralizing antibodies have been detected by sc

241 r, to date, HIV-1 Env immunogens that elicit broadly neutralizing antibodies have not been identified

242 Complexes of Env trimers with broadly neutralizing antibodies have surprisingly illust

243 he critical CDR-H2 Phe54 (F-alleles) to make broadly neutralizing antibodies (HV1-69-sBnAb) to the in

244 hether infection with a novel strain induced broadly neutralizing antibodies in humans.

245 ization resistant HIV-1 variants can lead to broadly neutralizing antibodies in some infected individ

246 Using the structure of a broadly neutralizing antibody in complex with a conserve

247 evaluate the impact of passive infusion of a broadly neutralizing antibody in newborns on the de novo

248 mised, passive immunization treatments using broadly neutralizing antibodies is a promising therapeut

249 rigin, maturation pathway, and prevalence of broadly neutralizing antibody lineages (Antibodyomics1,

250 promise in understanding the development of broadly neutralizing antibody lineages (bNAbs).

251 Characterizing epitopes of broadly neutralizing antibodies (NAbs), such as AR3A, is

252 ns potentially favors binding by established broadly neutralizing antibodies; omission of several spe

253 t strain-specific antibodies can evolve into broadly neutralizing antibodies or in some cases act as

254 at suggests general strategies for eliciting broadly neutralizing antibodies or preventing microbes f

255 120 variable regions 1 and 2 (V1V2)-targeted broadly neutralizing antibody PG9 to block productive in

256 In this study, we show that the broadly neutralizing antibody PGT121, which neutralized

257 ted CD4 T cells by the HIV envelope-specific broadly neutralizing antibody PGT121.

258 train B41 SOSIP.664 gp140, does not bind the broadly neutralizing antibody PGT151 and so was used her

259 he cytoplasmic tail and is stabilized by the broadly neutralizing antibody PGT151, at a resolution of

260 model to study the efficacy and mechanism of broadly neutralizing antibody protection against HIV acq

261 , our method provides critical insights into broadly neutralizing antibody recognition of Env, which

262 We apply this approach to PGT151, a broadly neutralizing antibody recognizing a combination

263 e the development of vaccines able to induce broadly neutralizing antibodies remains the ultimate goa

264 v conformation, preferentially recognized by broadly neutralizing antibodies, remains unknown.

265 tivating precursor B cell receptors of HIV-1 broadly neutralizing antibodies requires specifically de

266 ically infected individuals and found that a broadly neutralizing antibody response is protective and

267 bjects to investigate the molecular basis of broadly neutralizing antibody responses for diverse orth

268 high-yield subunit HCV vaccine that elicited broadly neutralizing antibody responses in preclinical t

269 However, which features confer potent and broadly neutralizing antibody responses is unclear.

270 ive association of A*03 with HIV-1-specific, broadly neutralizing antibody responses.

271 Stem-directed, broadly neutralizing antibodies (sBnAbs) targeting the i

272 Broadly neutralizing antibodies similar to the human V(H

273 viduals by passively administered 3BNC117, a broadly neutralizing antibody, suggested that the effect

274 tameric complex, rhesus macaques can develop broadly neutralizing antibodies targeting multiple immun

275 Broadly neutralizing antibodies targeting the Env glycan

276 Broadly neutralizing antibodies targeting the HIV-1 glyc

277 rove more capable of eliciting RBS-directed, broadly neutralizing antibodies than those produced from

278 Broadly neutralizing antibodies that bind to the highly

279 Here, we show that older individuals make broadly neutralizing antibodies that have no hemagglutin

280 increase the association of Env with potent broadly neutralizing antibodies that recognize the CD4-b

281 HIV-infected individuals eventually develop broadly neutralizing antibodies that recognize these vir

282 rement for accommodating glycans among known broadly neutralizing antibodies that target the glycan-s

283 re recognized by some of the most potent and broadly neutralizing antibodies to date.

284 s to HVR1 blocks the binding and activity of broadly neutralizing antibodies to HCV.

285 No immunogen to date has reliably elicited broadly neutralizing antibodies to HIV in humans or anim

286 dies in experimental animals have shown that broadly neutralizing antibodies to HIV-1 can prevent inf

287 on with natural immunity, we used a panel of broadly neutralizing antibodies to identify the immunoge

288 he human V(H)1-69 germline gene used by many broadly neutralizing antibodies to influenza A virus, Sa

289 strains, a vaccine most likely has to induce broadly neutralizing antibodies to the HIV-1 envelope gl

290 number of HIV-1-infected individuals develop broadly neutralizing antibodies to the virus (bNAbs).

291 ibitory antibodies and by blocking access of broadly neutralizing antibodies to their epitopes.

292 lization of an HIV-1 strain resistant to the broadly neutralizing antibodies VRC01 and 3BNC117.

293 ralization of HIV-1 strains resistant to the broadly neutralizing antibodies VRC01 and 3BNC117.

294 Infusion of the broadly neutralizing antibody VRC01 has been evaluated i

295 evaluate TDF and FTC in combination with the broadly neutralizing antibody VRC01-N using a highly rep

296 We found that broadly neutralizing antibodies were induced, but levels

297 s to conformation-specific, HA stem-directed broadly neutralizing antibodies with high affinity.

298 of trimer development programs is to induce broadly neutralizing antibodies with the potential to in

299 tant goal since tandem fusions contribute to broadly neutralizing antibodies with ultralong CDR3s.

300 activate B cells that express precursors of broadly neutralizing antibodies within polyclonal repert